Inhalation Sciences Q4: Rising revenues and close to break even - Redeye

Redeye provides an update in relation to ISAB’s Q4 2023 report. Revenues during the quarter amounted to SEK5.5m (SEK4.1m), and EBIT came in at SEK-0.7m (SEK-1.1m). Overall, the report came in a bit under our expectations; however, we still argue the quarter has been solid as revenues are rising and the company is close to profitability. Upon yesterday’s report, we make some short-term estimate changes, which results in an updated base case of SEK16.5 (17).

Länk till analysen i sin helhet: https://www.redeye.se/research/987123/inhalation-sciences-q4-rising-revenues-and-close-to-break-even?utm_source=finwire&utm_medium=RSS